TrialCNS drugs2018

Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Tobias Banaschewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.